Zeng, Shan

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Rha, S. Y., Oh, D.-Y., Yañez, P., Bai, Y., Ryu, M.-H., Lee, J., Rivera, F., Alves, G. V., Garrido, M., Shiu, K.-K., et al. (2023) · The Lancet Oncology

Gastric Cancer Management and OutcomesCancer Immunotherapy and Biomarkers

Cited by 690

PD-1/PD-L1 blockade enhances T-cell activity and antitumor efficacy of imatinib in gastrointestinal stromal tumors

Seifert, A. M., Zeng, S., Zhang, J. Q., Kim, T. S., Cohen, N. A., Beckman, M. J., Medina, B. D., Maltbaek, J. H., Loo, J. K., Crawley, M. H., et al. (2017) · Clinical Cancer Research

Gastrointestinal Tumor Research and TreatmentCancer Immunotherapy and Biomarkers

Cited by 149

A comprehensive analysis of the efficacy and safety of COVID-19 vaccines

Cai, C., Peng, Y., Shen, E., Huang, Q., Chen, Y., Liu, P., Guo, C., Feng, Z., Gao, L., Zhang, X., et al. (2021) · Molecular Therapy

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 146

MLH1 Deficiency Induces Cetuximab Resistance in Colon Cancer via Her‐2/PI3K/AKT Signaling

Han, Y., Peng, Y., Fu, Y., Cai, C., Guo, C., Liu, S., Li, Y., Chen, Y., Shen, E., Long, K., et al. (2020) · Advanced Science

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 34